# Valter Torri

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/valter-torri/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,272 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 89 |
| i10-index | 290 |
| Last Known Institution | Mario Negri Institute for Pharmacological Research |
| OpenAlex ID | https://openalex.org/A5010972450 |
| ORCID iD | https://orcid.org/0000-0001-9541-9354 |
| Works | 656 |

## Researcher papers

- [Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group](https://scholariq.org/papers/lung-adjuvant-cisplatin-evaluation-a-pooled-analysis-by-the-lace-collaborative/)
- [Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial](https://scholariq.org/papers/systematic-pelvic-lymphadenectomy-vs-no-lymphadenectomy-in-early-stage/)
- [Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial](https://scholariq.org/papers/paclitaxel-plus-platinum-based-chemotherapy-versus-conventional-platinum-based/)
- [Duration of Adjuvant Chemotherapy for Stage III Colon Cancer](https://scholariq.org/papers/duration-of-adjuvant-chemotherapy-for-stage-iii-colon-cancer/)
- [Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dual-targeted-therapy-with-trastuzumab-and-lapatinib-in-treatment-refractory/)
- [COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study](https://scholariq.org/papers/covid-19-in-patients-with-thoracic-malignancies-teravolt-first-results-of-an/)
- [Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group](https://scholariq.org/papers/meta-analysis-of-chemotherapy-in-head-and-neck-cancer-mach-nc-an-update-on-107/)
- [Adjuvant chemotherapy for resected early-stage non-small cell lung cancer](https://scholariq.org/papers/adjuvant-chemotherapy-for-resected-early-stage-non-small-cell-lung-cancer/)
- [Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial](https://scholariq.org/papers/safety-and-efficacy-of-preoperative-or-postoperative-chemotherapy-for-resectable/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)

## Researcher university

- [Mario Negri Institute for Pharmacological Research](https://scholariq.org/institutions/mario-negri-institute-for-pharmacological-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.